Financials in USD. Standardized financial statements.
A compact view of how RenovoRx, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $1.12M | $43,000 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +2511.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $327,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $796,000 | $43,000 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +70.9% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $13.31M | $11.01M | $11.40M | $9.95M | $5.67M | $3.20M | $3.90M |
| Operating Income? | -$12.51M | -$10.97M | -$11.40M | -$9.95M | -$5.67M | -$3.20M | -$3.90M |
| EBITDA? | -$12.51M | -$10.97M | -$11.39M | -$9.94M | -$5.48M | $0 | -$3.84M |
| Income Before Tax | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -$6.32M | -$3.80M | -$3.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -$6.32M | -$3.80M | -$3.84M |
| EPS? | $-0.32 | $-0.37 | $-0.50 | $-0.54 | $-0.40 | $-0.25 | $-0.22 |
| Diluted EPS? | $-0.32 | $-0.37 | $-0.50 | $-0.54 | $-0.40 | $-0.25 | $-0.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality